AMCP members are committed to a simple goal: providing the best available pharmaceutical care for all patients.

Visit us at www.amcp.org to learn more about the Academy of Managed Care Pharmacy and the opportunities we can offer.

IN THIS ISSUE

AMCP Partnership Forum Examines Rollout Issues of Biosimilars
AMCP District Days Informs Congressional Staff on Important Issues
New York Times Publishes Letter from AMCP CEO Edith A. Rosato
AMCP Corporate Member Profile: Danilo Verge of Novo Nordisk
AMCP Continues Advocacy on Biosimilars Issues
Lipscomb’s AMCP Chapter Expands Project to Help Seniors

LOOKING AHEAD

Webinar: Formulary Decision Focus – Assessing a Product’s Value | June 10
Webinar: Specialty Pharmacy: Next Generation Specialty Pharmacy | June 17
Webinar: The Role of Pharmacy in Alternative Payment Models | July 15
Webinar: Specialty Drug Management Trends | July 22

AMCP Partnership Forum Examines Rollout Issues of Biosimilars

Managed care pharmacy thought leaders from across the country will visit Washington, D.C., next week to discuss a wide range of biosimilar rollout issues at AMCP’s Partnership Forum, “Biosimilars: Ready, Set, Launch.” The June 10-11 event will explore how managed care pharmacy can work with key stakeholders to ensure a smooth launch of these therapies for patients, providers and payers alike. Among other things, attendees will examine the current state of preparedness for biosimilars, and offer recommendations for AMCP-developed training programs and resources to pave the way for their rapid uptake. The partnership forum is sponsored by Amgen, Merck, Momenta and Sandoz. Read more.
AMCP Members Educate Congressional Staff on Managed Care Pharmacy Issues During AMCP District Days

AMCP members last month took time out of their busy schedules to visit the district offices of their U.S. representatives and senators. During “AMCP District Days,” AMCP members educated Congressional staff on policy issues of concern to managed care pharmacy — a field that is still unfamiliar to many lawmakers. This year’s discussions centered on the importance of establishing drug management programs — sometimes referred to as “lock in” programs — in Medicare Part D to reduce opioid misuse and abuse among at-risk beneficiaries. (pictured from left: Cheryl Kaltz, BSPharm, MBA, RPh; Barbara McCallahan, Dir. of Comm. Affairs for Sen. Stabenow; and Gerard Franchina, Phd, MBA, BSPharm, RPh) Read more.

New York Times Publishes Letter from AMCP CEO Edith A. Rosato

The New York Times published a letter on May 11 from AMCP CEO Edith A. Rosato, RPh, IOM, objecting to the newspaper’s May 5 editorial supporting government price negotiations of pharmaceuticals. Rosato argues that government regulated prices can simply cause cost-shifting to other consumers. Read the letter and original editorial here.

AMCP Coverage of Meetings Keeps Members Informed on Developments in Cancer, Diabetes

The Academy is pleased to provide real-time coverage of scientific conferences relevant to AMCP members. AMCP recently delivered a series of Daily Reports from the 2015 Annual Meeting of the American Society of Clinical Oncology®, held May 29-June 2 in Chicago, Ill. AMCP will provide a Daily Report of the American Diabetes Association’s 75th Scientific Sessions, June 5-9 in Boston, Mass. Keep an eye out for this in your email. Members may also access the coverage at www.amcp.org/proceedings.
Save the Date! AMCP Nexus 2015

Mark your calendars! AMCP Nexus 2015 takes place Monday-Thursday, Oct. 26-29 at the Gaylord Palms Hotel & Convention Center in Orlando, Florida.

*Registration opens June 23 at 1 p.m. Eastern Time.* Check AMCP’s homepage soon for more details: [www.amcp.org](http://www.amcp.org)

Meanwhile, AMCP continues to invite proposals for fully funded industry-sponsored satellite symposia to be conducted in conjunction with AMCP Nexus 2015. For information on this opportunity, visit [here](#).

AMCP Corporate Member Profile: Danilo Verge, VP, Medical Affairs, Diabetes and Obesity, Novo Nordisk

AMCP caught up recently with Danilo Verge, MD, MBA, VP Medical Affairs, Diabetes and Obesity for Novo Nordisk, to get his thoughts on becoming an AMCP Corporate PLUS Member and where he sees the company headed throughout 2015.

**News&Views: As you considered becoming an AMCP Corporate PLUS Member, what tipped the scales?**

**Verge:** As an established leader in diabetes care and an emerging leader in obesity care, Novo Nordisk is constantly striving for innovative ways to reach patients, bringing them information, tools and treatments that will help them better manage their diabetes for years to come. The AMCP Corporate Member PLUS offers more opportunities to access AMCP members who, like us, are working to improve the lives of millions of Americans with diabetes. Read [more](#).
AMCP Continues Advocacy to Ensure Biosimilars Share Common Names with Reference Products

With the FDA expected soon to issue final guidance on biosimilar naming policies, AMCP continues to meet with key officials at the Department of Health and Human Services to advocate for the adoption of common international nonproprietary names without prefixes or suffixes. AMCP recently presented HHS with findings of a survey published in the March Journal of Managed Care & Specialty Pharmacy showing that 75% of pharmacists surveyed would be more confident in dispensing an interchangeable biosimilar that shares a name with the reference product. In comparison, 53% said they would not be confident in dispensing an interchangeable biosimilar that does not share a nonproprietary name with the reference product. Read more.

AMCP Chapter at Lipscomb University Expands Project to Help Seniors

Student pharmacists in the AMCP Chapter at Lipscomb University College of Pharmacy saw additional possibilities in their partnership with the Tennessee State Health Insurance Assistance Program helping seniors enroll in Medicare. As the enrollment period ended, chapter members wanted to keep building on the relationships they had developed with the seniors they had served. The student pharmacists proposed offering a series of health services to this community, including health screenings; point-of-care device demonstrations (i.e. blood glucose meters); proper medication techniques (i.e. asthma inhalers); and educational seminars ranging from drug topics and disease states to how to access medication therapy management programs. (pictured: Lipscomb student pharmacists Amanda Gani and Bryan Davis) Read more.

Comparative Effectiveness Research: Two Options To Complete Certificate Program!
Formulary decision-makers increasingly must make life-and-death decisions based on new kinds of research that are often of unfamiliar design. Adequate training in how to use and evaluate different research models, including indirect treatment comparisons and observational research, is becoming a critical component in the managed care pharmacist’s toolkit. The **Comparative Effectiveness Research Certificate Program**, presented jointly by AMCP, the International Society for Pharmacoeconomics and Outcomes Research, and the National Pharmaceutical Council, is an in-depth program that guides pharmacists and other clinical decision-makers in how to assess evidence produced by new, and perhaps, unfamiliar research designs. [Register by Aug. 14](https://www.magnetmail.net/design/preview.cfm?version=HTML&message_id=10250790)

Making Better Use of Industry Pharmacoeconomic Models

A survey of AMCP eDossier System users explored the attitudes and perspectives of health care decision makers (HCDMs) on the use of models provided by Life Sciences Organizations. The results of the survey were presented as part of a workshop at the recent ISPOR Annual International Meeting and focused on how and when industry models can make an effective contribution to formulary decision-making. The survey found that over 75% of respondents reported that HCDMs sometimes or often consulted industry models. Read [more](https://www.magnetmail.net/design/preview.cfm?version=HTML&message_id=10250790).